Akilov Oleg E, Geskin Larisa
Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA.
Skin Therapy Lett. 2011 Feb;16(2):1-5.
A variety of novel therapeutic modalities have recently become available for patients with cutaneous T cell lymphoma (CTCL). In particular, with recent FDA approvals of the three new agents vorinostat (Zolinza), romidepsin (Istodax), and pralatrexate (Folotyn) CTCL treatment has been transformed. Here, we offer a brief overview of these agents and discuss their place in the spectrum of current therapies for CTCL.
最近，多种新型治疗方式已可供皮肤T细胞淋巴瘤（CTCL）患者使用。特别是，随着美国食品药品监督管理局（FDA）最近批准了三种新药：伏立诺他（Zolinza）、罗米地辛（Istodax）和普拉曲沙（Folotyn），CTCL的治疗发生了变革。在此，我们简要概述这些药物，并讨论它们在CTCL当前治疗方案中的地位。
